Tag
An international multicenter cohort of 1,883 patients with radiologically growing vestibular schwannomas treated first‑line with radiotherapy showed a 10‑year tumor control rate of 76.1% (primary definition). Control estimates varied widely
A secondary analysis of the PROTECT trial reveals cribriform-positive prostate cancer significantly elevates 15-year metastasis risk, with radiotherapy plus neoadjuvant ADT reducing this risk more effectively than surgery or active monitori
This clinical trial prospectively evaluates how a 12-gene expression assay (DCIS score) guides postoperative radiotherapy decisions after breast-conserving surgery in ductal carcinoma in situ, showing tailored radiotherapy use may reduce ip
A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiot
A randomized trial demonstrates that modified target delineation integrating multimodal MRI and white matter tractography with moderately hypofractionated radiotherapy achieves comparable survival outcomes to standard IMRT while reducing ir
The UPGRADE-RT multicenter trial confirms that lowering elective neck irradiation dose in definitive radiotherapy for head and neck cancer maintains disease control and improves quality of life, reducing toxicity without increasing recurren
The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.
